Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and ...

An international team of researchers has forced light to replicate the quantum Hall effect, a Nobel Prize–winning phenomenon ...

Explore how proteomics transforms pharmaceutical R&D, from drug discovery to biomarker qualification and clinical development ...

Mechanisms and Frontiers of Treatment for Diabetes-Related Epilepsy. Journal of Biosciences and Medicines, 14, 57-73. doi: 10.4236/jbm.2026.143006 . Diabetes mellitus (DM) is a metabolic disease ...

We look forward to sharing additional Phase 1/2 data next week at the Muscular Dystrophy Association's annual meeting and ...

EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the ...

In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified ...

Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation.

This study presents valuable findings for identifying biotypes of depression patients using white matter measures, which are under-utilised and under-appreciated in current biological and ...

Company announcement Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00 EET Herantis Pharma releases 2H and FY 2025 report today Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herant ...

Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as ...